Search

Pomalidomide prolongs survival in refractory myeloma patients

MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…

Read more

EHA-Baltic Hematology Tutorial on Lymphoid Malignancies, including Waldenström's Macroglobulinemia

EHA in close collaboration with the Estonian Society of Haematology, the Lithuanian Society of Hematology and the Latvian Hematology Society are organizing the first EHA-Baltic Hematology Tutorial on Lymphoid Malignancies, including Waldenström's Macroglobulinemia.

Read more

Standards for functional precision medicine project update, December 2023

A project update from Prof Philipp Staber. We're confident that we'll successfully finish our SWG-initiated small research project, ‘standards for functional precision medicine (StFPM),’ within the next six months.

Read more

Hematology Jobs

In this section of the EHA website, job opportunities within the field of hematology are posted, when available. Regulations

Service meant for hematologists and related disciplines.

Read more

Adult Acute Lymphoblastic Leukemia

The Specialized Working Group on Adult Acute Lymphoblastic Leukemia consists mainly of the members of the EWALL group, which is the European Working Group for Adult ALL. This includes the leaders of the national ALL study groups in Europe.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more